Geno J. Germano was appointed Director of Eloxx Pharmaceuticals, Inc. As of November 6, 2026, Eloxx Pharmaceuticals, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 1, 2026 to October 22, 2026, naming 2 appointments (Form 8-K, October 22, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Eloxx Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Eloxx Pharmaceuticals, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-01 to 2026-10-22. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Eloxx Pharmaceuticals, Inc. files it.
Also on the record for Eloxx Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by Nantahala Capital Management, LLC | 9.91% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Srinivas Akkaraju | 9.9% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G, by Aberdeen Group plc | 9.91% of the class | 5%+ stakes | Source |
| June 17, 2026 | Stake report, Schedule 13G, by Coastlands Capital LP | 9.99% of the class | 5%+ stakes | Source |
| June 17, 2026 | Stake report, Schedule 13G, by Domicilium Capital Partners LLC | 19.99% of the class | 5%+ stakes | Source |
| June 16, 2026 | Stake report, Schedule 13G, by EcoR1 Capital, LLC | 9.9% of the class | 5%+ stakes | Source |
| June 16, 2026 | Stake report, Schedule 13G, by Stonepine Capital Management, LLC | 9.9% of the class | 5%+ stakes | Source |
| June 15, 2026 | Stake report, Schedule 13G, by Raymond Debbane | 9.99% of the class | 5%+ stakes | Source |
| June 5, 2026 | Stake report, Schedule 13G/A, by Domicilium Capital Partners LLC | 4.9% of the class | 5%+ stakes | Source |
| May 29, 2026 | Stake report, Schedule 13G/A, by Coastlands Capital LP | 4.99% of the class | 5%+ stakes | Source |
| May 4, 2026 | Stake report, Schedule 13G, by Domicilium Capital Partners LLC | 18.6% of the class | 5%+ stakes | Source |
| May 1, 2026 | Stake report, Schedule 13G, by Coastlands Capital LP | 16.51% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Eloxx Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Eloxx Pharmaceuticals, Inc. and the records around it.
Eloxx Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Aberdeen Group plc also filed stake reports on 12 other companies: Equillium, Inc. (Nov 2026), IMMUNIC, INC (Nov 2026), CODEXIS, INC. (Oct 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026), KALARIS THERAPEUTICS, INC. (May 2026)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)
Watch Eloxx Pharmaceuticals, Inc.
Get an email when Eloxx Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Eloxx Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Eloxx Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eloxx Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-22 | In | Director | 8-K, 2026-10-22 | ||
| 2026-06-01 | In | Director | 8-K, 2026-06-01 |
Who leads Eloxx Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Geno J. Germano, appointed (filed 2026-10-22).
New leaders reset buying decisions — get the Full Report on Eloxx Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Eloxx Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Director at Eloxx Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: Geno J. Germano, Director
On October 19, 2026, the Board of Directors (the "Board") of Eloxx Pharmaceuticals, Inc. (the "Company") increased the size of the Board from five to six directors and appointed Geno J. Germano to fill the newly created vacancy on the Board.
- Mr. Germano will serve for a term expiring at the Company's annual meeting of stockholders to be held in 2027 and until his successor is duly elected and qualified or until his earlier death, disqualification, resignation or removal.
- The Board has determined that Mr. Germano is "independent" in accordance with the listing standards of the Nasdaq Stock Market LLC, the Company's internal policies, and the rules and regulations of the Securities and Exchange Commission (the "SEC").
- Geno J. Germano is a 35-year veteran of the pharmaceutical and life sciences industry with extensive experience in development and commercialization of a broad range of medicines across most therapeutic categories.
- Most recently, from August 2018 to June 2024, Mr. Germano served as President and Chief Executive Officer and a board member of Elucida Oncology, Inc., a biotechnology company.
- He previously served as President of Intrexon Corporation, or Intrexon, a leader in engineering and industrialization of biology, from June 2016 to March 2017.
- Prior to joining Intrexon, from 2014 to February 2016, Mr. Germano was Group President of the Global Innovative Pharma Business of Pfizer, where he led a growing global $14 billion business with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas.
Appointed: Stephen W. Webster, Director
Director Appointments On May 27, 2026, the Board of Directors (the "Board") of Eloxx Pharmaceuticals, Inc. (the "Company") appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board, and reduced the size of the Board from six to five directors.
- Mr. Webster has also been appointed to serve as a member of each of the Audit Committee and Nominating & Corporate Governance Committee of the Board.
- Ms. Kjellson has also been appointed to serve as a member of each of the Compensation Committee and Nominating & Corporate Governance Committee of the Board.
- Stephen Webster Mr. Webster will serve for a term expiring at the Company's annual meeting of stockholders to be held in 2027 and until his successor is duly elected and qualified or his earlier death, disqualification, resignation or removal.
- The Board has determined that Mr. Webster is "independent" in accordance with the listing standards of the Nasdaq Stock Market, LLC, the Company's internal policies, and the rules and regulations of the Securities and Exchange Commission (the "SEC").
- The Board has also determined that Mr. Webster qualifies as a "financial expert" pursuant to the SEC rules in connection with his appointment to the Audit Committee.
- Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, Inc., a publicly traded biotechnology company, from July 2014 until its acquisition by the Roche Group in December 2019.
Tools for this story
Each opens in a new tab, filled in for Eloxx Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.